Cost-effectiveness of abiraterone treatment in patients with castration-resistant prostate cancer who previously received docetaxel therapy

<p><strong>Background.</strong> Therapy for metastatic castration-resistant prostate cancer (CRPC) is a serious problem that requires significant public health care expenditures.</p><p><strong>Objective</strong>: to evaluate the cost-effectiveness of abirate...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: A. V. Rudakova, D. O. Meshkov, S. V. Mishugin
Formato: Artigo
Idioma:Russo
Publicado: ABV-press 2014-11-01
Series:Onkourologiâ
Assuntos:
castration-resistant prostate cancer
chemotherapy
docetaxel
abiraterone
survival
cost effectiveness
Acceso en liña:http://oncourology.abvpress.ru/index.php/oncur/article/view/383
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares